Testimonials

Background stories of how others approached and experienced their European Horizon funding trajectory.

UNCHAIN - Revolutionising urban logistics & space management

image of UNCHAIN - Revolutionising urban logistics & space management

Published on | 1 day ago

Programmes Climate, Energy, Mobility

The UNCHAIN project, ‘urban logistics and planning: anticipating urban freight generation and demand including digitalisation of urban freight’ obtained funding from the Horizon Europe’s Mobility Cluster. The project focuses on breaking down data silos and promoting public-private data exchange across a unified European mobility data space, enabling more informed decisions and greater efficiency. The City of Mechelen is a partner in the project and takes on the role of ‘follower city’: it will work alongside the primary demonstration sites (in Madrid, Berlin and Florence) to maximize the geographical coverage and replicability of solutions across Europe. Mechelen aims to test 2 concrete solutions in the UNCHAIN project, with the aim to help addressing its current and future challenges in urban freight distribution.

Read the full article for details 
Other available testimonials

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.